Report: Biotech licensing, M&A deals dropped in 2012

04/1/2013 | Genetic Engineering & Biotechnology News

Biotech and biopharmaceutical firms struck fewer licensing and acquisition deals in 2012 compared with 2011, perhaps fueled by greater confidence in drug pipelines and fewer worries about patent expirations, according to a new report from EP Vantage. Total licensing-deal value declined 19%, to $20.9 billion, and the number of products licensed dropped from 1,037, to 759. Merger and acquisition deals reached $42.6 billion, down 24%.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director Quality Improvement
Molina Healthcare of Texas
San Antonio, TX
Senior Medical Director
Network Health
Medford, MA
SVP/Head of Health Plans and Managed Care
Avalere Health
Washington, DC
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR